# Aerosol Combination Therapy of All-trans Retinoic Acid and Isotretinoin as A Novel Treatment for Inducing Neutralizing Antibodies in COVID -19 Infected Patients Better Than Vaccine : An Innovative Treatment

> **NCT04396067** · PHASE2 · UNKNOWN · sponsor: **Kafrelsheikh University** · enrollment: 360 (estimated)

## Conditions studied

- COVID-19

## Interventions

- **DRUG:** Aerosolized 13 cis retinoic acid
- **DRUG:** Aerosolized All trans retinoic acid
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT04396067
- **Lead sponsor:** Kafrelsheikh University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-10
- **Primary completion:** 2020-10
- **Final completion:** 2020-12
- **Target enrollment:** 360 (ESTIMATED)
- **Last updated:** 2020-10-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04396067

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04396067, "Aerosol Combination Therapy of All-trans Retinoic Acid and Isotretinoin as A Novel Treatment for Inducing Neutralizing Antibodies in COVID -19 Infected Patients Better Than Vaccine : An Innovative Treatment". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT04396067. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*